Imagine a hidden seed in the liver that can wake up and cause malaria even after you feel healthy. Standard tests can't find these seeds, but this project uses a blood test to spot people likely to have them. Once identified, they get a specific drug to clear the liver and a mobile app to track the process.
Current malaria diagnostics cannot detect dormant liver forms, leading to either missed infections or the dangerous over-prescription of drugs to entire populations.
A serological diagnostic test for P. vivax, a mobile-technology interface for point-of-care guidance, and machine learning models for population surveillance.
If you are a diagnostic company dealing with the inability of current tests to detect latent malaria—this project developed a serological test that identifies individuals carrying hypnozoites. This allows for targeted treatment rather than treating everyone. This expands the addressable market for specialized malaria diagnostics.
If you are a software firm dealing with inefficient rural health data collection—this project developed mobile technologies that interface with diagnostic tests to guide treatment decisions. This creates a scalable model for managing public health interventions in remote areas. It integrates clinical data with real-time decision support.
If you are a pharma company dealing with the risk of dangerous side effects from mass drug administration—this project developed a way to use serology to target primaquine only to those who need it. This reduces unnecessary drug exposure and improves safety profiles. It optimizes the delivery of existing treatments.
Based on available project data, the specific cost per test is not mentioned.
The project is testing the intervention via a Cluster-Randomised Trial in Ethiopia and Madagascar, which provides the necessary data to evaluate scalability in high-burden regions.
Based on available project data, there is no mention of specific patents or licensing agreements.
The project is refining mobile technologies that interface with point-of-care tests to guide treatment decisions and align with existing health system structures.
The project period runs from 2022-10-01 to 2027-09-30, with initial clinical studies already initiated within the first 18 months.
The consortium is research-heavy, consisting of 9 partners across 9 countries. It is led by the Institut Pasteur and includes 4 research organizations and 3 universities. With only 1 industry partner (an 11% ratio) and 1 SME, the group is currently focused on clinical validation and public health evidence rather than immediate commercialization.
Contact Institut Pasteur (FR) regarding the PvSeroTAT intervention
Contact us to identify licensing opportunities for the P. vivax serological test.
